1-thia-5-aza-bicyclo (4.2.0) Octane Ring Containing (including Dehydrogenated) (e.g., Cephalosporins, Etc.) Patents (Class 514/200)
  • Publication number: 20030096006
    Abstract: An antibiotic product for delivering at least cephalosporin or Metronidazole that is comprised of three dosage forms with different release profiles with each of cephalosporin and Metronidazole being present in at least one of the dosage forms.
    Type: Application
    Filed: March 7, 2002
    Publication date: May 22, 2003
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
  • Patent number: 6565882
    Abstract: Antibiotic composition having four dosage forms with different release profiles providing for initial release of a beta lactam antibiotic followed by release of a beta-lactamase inhibitor, followed by release of the antibiotic followed by release of the inhibitor. In a preferred embodiment, release from the second, third and fourth dosage forms is initiated after the component released from the immediately previous form reaches Cmax.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: May 20, 2003
    Inventor: Edward M. Rudnic
  • Publication number: 20030092696
    Abstract: The invention provides compounds of formula (I): 1
    Type: Application
    Filed: July 24, 2002
    Publication date: May 15, 2003
    Inventors: John D. Buynak, Lakshminarayana Vogeti
  • Publication number: 20030092682
    Abstract: A method of treating (a) cold sores in and out of the mouth, (b) canker sores, (c) cancer wounds including but not limited to wounds such as those which fail to heal due to chemotherapy and radiation therapy, (d) surgical wounds of all types, (e) diabetes wounds, (f) decubitus ulcers, (g) athletes foot including chronic athletes foot and (h) scarring with doxycycline and/or cefaclor is disclosed.
    Type: Application
    Filed: July 20, 2001
    Publication date: May 15, 2003
    Inventor: Gary V. Heesch
  • Publication number: 20030087823
    Abstract: The present invention relates to the use of endotoxin neutralizing protein (ENP) and derivatives thereof as stand alone microbial inhibitors or as synergistic enhancers of antibiotics and preservatives. Compositions comprising ENP or alone or in combination with an antibiotic may be used to prevent or treat gram-negative bacterial infections, endotoxemia, septic shock, gram-positive bacterial infections, yeast infections and fungal infections.
    Type: Application
    Filed: September 11, 2002
    Publication date: May 8, 2003
    Applicant: Associates of Cape Cod, Inc.
    Inventors: Erik J. Paus, Norman R. Wainwright
  • Publication number: 20030078194
    Abstract: The present invention provides pro-micelle compositions comprising a pharmaceutically active agent encapsulated with a membrane of esterified C12-C18 fatty acids. In the mammalian intestine, exposure to C12-C18 fatty acids results in conversion of the pro-micelle to a stable micelle that effectively delivers the pharmaceutically active agent to the systemic circulation. The present invention further provides methods of making and using such compositions.
    Type: Application
    Filed: October 11, 2001
    Publication date: April 24, 2003
    Inventors: Young W. Cho, Kwang-Ho Lee
  • Publication number: 20030069220
    Abstract: A method of treating a plurality of individuals exposed to a biological agent is disclosed. The method includes distributing a sufficient amount of an aqueous solution. The aqueous solution is a palatable concentration of a cephalosporin or its equivalent mixed with a specified hydroxypolycarboxylic acid. The aqueous solution having a weight ratio of the hydroxypolycarboxylic acid to cephalosporin or its equivalent of at least about 1.8.
    Type: Application
    Filed: September 27, 2001
    Publication date: April 10, 2003
    Inventor: Michael Strobel
  • Publication number: 20030060451
    Abstract: A method for enhancing the oral bioavailability of a prodrug ester by formulating the ester as a non-emulsified formulation with lecithin; as well as a pharmaceutical composition of at least one antibiotic and lecithin in a non-emulsified formulation; a method of treating infections with the non-emulsified formulation, and a method for preparing tablets by direct compression of blends of drugs with lecithin are disclosed. Non-emulsified formulations include solids, tablets, capsules, lozenges, suspensions, elixirs and solutions, and exclude emulsions, liposomes, lipid matrix systems and micro-emulsions. A suitable prodrug ester is a cephalosporin &bgr;-lactam antibiotic such as cefditoren pivoxil, and a suitable non-emulsified formulation is a solid formulation.
    Type: Application
    Filed: May 28, 2002
    Publication date: March 27, 2003
    Inventors: Rajneesh Taneja, Dale Brinker, Jacqueline Briskin, Dilip Vishwasrao, Roberto Aponte, Pramod Gupta
  • Patent number: 6537985
    Abstract: An antibiotic formulation in a true solution is provided. This formulation includes an antibiotic and N-methyl-2-pyrrolidone. It also may include a preservative, an antioxidant, and/or an additive. The antibiotic is a beta lactam, such as a penicillin, a cephalosporin, other beta lactams, or combinations thereof. The formulation is made by dissolving the antibiotic in the N-methyl-2-pyrrolidone. The antibiotic formulation is suitable for use at temperatures below about 0° C. and without agitation. Further, the antibiotic formulation in true solution can be made with non-sterile ingredients and can be filtered to remove impurities.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: March 25, 2003
    Assignee: Phoenix Scientific, Inc.
    Inventors: Richard Mihalik, John R. Carpenter, Heidi M. P. Faris
  • Patent number: 6537984
    Abstract: Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.
    Type: Grant
    Filed: June 19, 2001
    Date of Patent: March 25, 2003
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Pharmagenesis
    Inventors: Glenn D. Rosen, Edwin S. Lennox, John H. Musser
  • Patent number: 6531465
    Abstract: A compound of formula wherein Ac, R1 and R2 have various meanings, a process for a preparation thereof and its use as a pharmaceutical, i.e. as antibacterial agent.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: March 11, 2003
    Assignee: Biochemie Gesellschaft m.b.H.
    Inventors: Gerd Ascher, Johannes Ludescher
  • Publication number: 20030036541
    Abstract: The invention provides compounds of formula I and IV: 1
    Type: Application
    Filed: May 10, 2002
    Publication date: February 20, 2003
    Applicant: Research Corporation Technologies, Inc.
    Inventors: John D. Buynak, A. Srinivasa Rao, Greg C. Adam, Sirishkumar D. Nidamarthy, Venkata Ramana Doppalapudi
  • Publication number: 20030032600
    Abstract: This invention is directed to a taste masked liquid pharmaceutical composition comprising a pharmaceutically active agent and a taste masking composition. In particular, the taste masking composition comprises a taste masking effective amount of an artificial sweetener.
    Type: Application
    Filed: February 26, 2002
    Publication date: February 13, 2003
    Inventors: Stephen A. Ulrich, Karen R. Zimm, Marc Karel Jozef Francois, Willy Maria Albert Carlo Dries
  • Publication number: 20030012755
    Abstract: Mammalian hair growth is reduced by applying an inhibitor of telomerase to the skin.
    Type: Application
    Filed: June 27, 2001
    Publication date: January 16, 2003
    Inventors: Peter Styczynski, Gurpreet S. Ahluwalia
  • Publication number: 20030008844
    Abstract: The present invention is directed to methods for preventing or treating inflammatory bowel disease by administering a composition comprising a therapeutically or prophylactically effective amount of a composition comprising between about 60% to 90% iduronylglycosaminoglycan sulfate and between about 10% to 40% dermatan sulfate, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof. In a particular embodiment, a therapeutically or prophylactically effective amount of a composition comprising sulodexide, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof is administered. The composition to be administered may also comprise one or more additional active ingredients selected from the group consisting of steroids, aminosalicylates, short-chain fatty acids, thioguanine derivatives, antibiotics, biological agents, antidepressants, and pain-relievers.
    Type: Application
    Filed: May 16, 2002
    Publication date: January 9, 2003
    Applicant: Keryx Biopharmaceuticals, Inc.
    Inventors: Michael Spero, Noa Shelach, Morris Laster
  • Publication number: 20030008858
    Abstract: A method for improving sexual function is described. A mammal suffering from sexual dysfunction or otherwise in need of enhanced sexual function is administered a compound selected from those that are capable of inhibiting the activity of &bgr;-lactams, penicillin-binding protein, carboxypeptidase,. Such compounds, including particularly &bgr;-lactam ring-containing compounds, can be used to formulate pharmaceutical formulations useful for improving sexual function.
    Type: Application
    Filed: June 18, 2002
    Publication date: January 9, 2003
    Inventor: Gay A. Koppel
  • Publication number: 20020198186
    Abstract: A novel lyophilizate and method of preparation as well as the use of the lyophilizate to treat female infertility and for gonad protection. Cetrorelix is dissolved in acetic acid 30% V/V, the solution is transferred to water and freeze dried.
    Type: Application
    Filed: May 24, 2002
    Publication date: December 26, 2002
    Applicant: Zentaris AG
    Inventors: Jurgen Engel, Burkhard Wichert, Dieter Sauerbier, Thomas Reissmann
  • Publication number: 20020192281
    Abstract: This invention provides &bgr;-lactam antibiotic-containing tablets capable of being orally taken either as such owing to their being small-sized, hence still easily swallowable, or, in the case of administration to the aged encountering some difficulty in swallowing, in the form of dispersions resulting from easy self-disintegration upon being dropped into water in a glass as well as a method of producing the same. The tablets of this invention comprise, on the per-tablet basis, 60-85% by weight of a &bgr;-lactam antibiotic, 1-10% by weight of low-substituted hydroxypropylcellulose and/or crosslinked polyvinylpyrrolidone as a disintegrator, and 0.5-2% by weight of a binder. Granules to be compressed for tableting are prepared using water or an aqueous solution of ethanol or the like.
    Type: Application
    Filed: May 28, 2002
    Publication date: December 19, 2002
    Applicant: Fujisawa Pharmaceutical Co., Ltd.
    Inventor: Hisami Yamaguchi
  • Publication number: 20020182207
    Abstract: The present invention provides a method of modifying a target substance by contacting the target substance with a catalyst that catalyzes the modification of the target substance. In a preferred embodiment, the method comprises labeling a target substance by contacting the target substance with a label and a catalyst that catalyzes the attachment of the label to the target substance. Preferably, the catalyst catalyzes selectively the reaction between a specific target molecule and a specific label. The attachment of labels may be used to inactivate a biologically active target substance or otherwise modulate its activity. Alternatively, the method may be used to label the target molecule with a detectable label suitable for the sensitive detection of the target substance.
    Type: Application
    Filed: October 19, 2001
    Publication date: December 5, 2002
    Inventor: Martin T. Martin
  • Patent number: 6489319
    Abstract: Administration of inhibitors of carboxypeptidase E provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior and enhanced cognition. Certain &bgr;-Lactam antibiotics, most significantly, certain 1-oxa-1-dethia cephems with blood brain barrier transport, exhibit potent therapeutic neurologic activity.
    Type: Grant
    Filed: February 14, 2001
    Date of Patent: December 3, 2002
    Assignee: Revaax Pharmaceuticals, LLC
    Inventors: Gary A. Koppel, Michael O. Chaney
  • Patent number: 6486149
    Abstract: Processes are provided for the preparation of orally administrable, yellow and powdery compositions essentially consisting of particles composed of a homogeneous mixture of an amorphous Cefditoren pivoxil substance with a water soluble high-molecular additive. These compositions can be produced by dissolving crystalline Cefditoren pivoxil substance and the water-soluble high-molecular additive in an aqueous solution of an acid, then neutralizing the resultant solution, to co-precipitate the product, and drying the thus precipitated product, followed by recovering the product in the form of the above-mentioned particles.
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: November 26, 2002
    Assignee: Meiji Seika Kaisha Ltd.
    Inventors: Masahiro Onodera, Masamichi Sukegawa, Kiyoshi Yasui, Tatsuo Watanabe, Toyomi Sato, Yasushi Murai, Katsuharu Iinuma
  • Publication number: 20020172668
    Abstract: Disclose herein is a novel recombinant mutant protein of human Group IIA phospholipase A2 (PLA2) which has enhanced antibacterial activity when compared to the wild-type human Group IIA PLA2, pharmaceutical formulations comprising the protein and methods of use thereof. Additionally, the formulations may comprise other bioactive compounds, such as, e.g., conventional antibiotics, that act additively or synergistically with Group IIA PLA2 in order to promote bacterial killing.
    Type: Application
    Filed: December 18, 2000
    Publication date: November 21, 2002
    Applicant: New York University
    Inventors: Jerrold Weiss, Peter Elsbach, Ning Sheng Liang
  • Publication number: 20020165130
    Abstract: A method of promoting the uptake of exogenous antimicrobial compounds by microbial cells is disclosed. In one embodiment, the method comprises the step of exposing the microbial cell to an amount of at least one sesquiterpenoid effective to enhance antimicrobial compound uptake in a microorganism and an antimicrobial compound. An antimicrobial composition comprising at least one sesquiterpenoid and an antimicrobial compound, the sesquiterpenoid being present in a concentration of between 0.1 mM and 50 mM, is also disclosed.
    Type: Application
    Filed: September 25, 2001
    Publication date: November 7, 2002
    Inventors: Eric A. Johnson, Byron F. Brehm-Stecher
  • Publication number: 20020155094
    Abstract: The invention relates to the method of preventing and treating sepsis and ARDS using chemokine or biologically active fragment thereof, alone or in conjunction with an anti-infective agent.
    Type: Application
    Filed: March 25, 2002
    Publication date: October 24, 2002
    Applicant: Smithkline Beecham Corporation
    Inventors: John R. White, Louis M. Pelus
  • Patent number: 6468964
    Abstract: According to the present invention there is provided a method for the treatment or prophylaxis of acidic gut syndrome resulting from the accumulation of acid and production of endotoxin in the gastrointestinal tract of a human or an animal, said accumulation resulting from the fermentation of carbohydrate in the gastrointestinal tract of said human or animal, wherein said method comprises administering to said human or animal an effective amount of an active agent capable of preventing or controlling acid and endotoxin accumulation in the gastrointestinal tract.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: October 22, 2002
    Assignee: University of New England, of Armidale
    Inventor: James Baber Rowe
  • Publication number: 20020150617
    Abstract: The present invention provides a method of making tablet compositions that are substantially free of excipients. The method includes forming a compactable granular mixture containing at least one compaction enhancing therapeutic compound, at least one other therapeutic compound that is different form the compaction enhancing therapeutic compound, and less than about 15 weight percent of a non-aesthetic excipient. The compactable granular mixture thus obtained is compressed to form a tablet composition. The present invention also provides tablet compositions produced by the methods of the present invention that are substantially free of excipients.
    Type: Application
    Filed: January 29, 2002
    Publication date: October 17, 2002
    Applicant: Rexall Sundown, Inc.
    Inventors: William J. Mergens, Kuei Tu Chang, Gerald T. Holly
  • Publication number: 20020146390
    Abstract: The invention relates to the method of preventing and treating sepsis and ARDS using chemokine or biologically active fragment thereof, alone or in conjunction with an anti-infective agent.
    Type: Application
    Filed: March 28, 2002
    Publication date: October 10, 2002
    Inventors: John Richard White, Louis Martin Pelus
  • Patent number: 6461607
    Abstract: The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds.
    Type: Grant
    Filed: August 5, 1999
    Date of Patent: October 8, 2002
    Assignee: Ganeden Biotech, Inc.
    Inventor: Sean Farmer
  • Publication number: 20020141972
    Abstract: The invention relates to the method of preventing and treating sepsis and ARDS using chemokine or biologically active fragment thereof, alone or in conjunction with an anti-infective agent.
    Type: Application
    Filed: March 26, 2002
    Publication date: October 3, 2002
    Applicant: Smithkline Beecham Corporation
    Inventors: John Richard White, Louis Martin Pelus
  • Publication number: 20020115642
    Abstract: The present invention provides compositions comprising improved beta-lactam antibiotics and methods for applying these compositions to inhibit the growth of microbial infections. The improved antibiotics are capable of inhibiting the growth of both antibiotic sensitive and antibiotic resistant microorganisms In addition, the invention provides methods for treating a subject infected with a microorganism by administering the compositions of the invention.
    Type: Application
    Filed: May 1, 2001
    Publication date: August 22, 2002
    Inventors: Ming Fai Chan, Rosario S. Castillo, Qing Li, Venkata Ramana Doppalapudi, Mark Stephen Hixon, Thomas J. Lobl
  • Publication number: 20020103181
    Abstract: A pharmaceutical composition in the form of a tablet for controlled release of an active ingredient comprises a betalactam antibiotic such as cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters as active ingredient, and a mixture of hydrophilic polymers selected from the group consisting of at least one sodium alginate and at least one xanthan gum as controlled release matrix; and optionally probenecid as an antibiotic adjuvant as either immediate release or controlled release part. The composition may also contain one or more of a water soluble and/or water dispersible diluent, wherein the quantities of the hydrophilic polymers and water soluble and/or water dispersible diluents are such that the therapeutically effective active ingredient is released at a rate suitable for once or twice daily administration of the pharmaceutical composition.
    Type: Application
    Filed: November 30, 2000
    Publication date: August 1, 2002
    Applicant: LUPIN LABORATORIES LIMITED
    Inventors: Himadri Sen, Rajesh Suresh Kshirsagar, Chandrashekhar Shriram Kandi, Shailesh Suresh Bhamare
  • Patent number: 6420355
    Abstract: A pharmaceutical composition in the form of an emulsion preconcentrate for oral administration and containing a cyclosporin. The pharmaceutical composition has a carrier medium for the cyclosporin that contains a hydrophilic organic solvent; a mixed mono-, di-, and tri-glyceride or a transesterified and polyethoxylated vegetable oil; and a polyoxyethylene-sorbitan-fatty acid ester surfactant. The pharmaceutical composition provides high bioavailability and low inter- and intra-subject variability.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: July 16, 2002
    Assignee: Novartis AG
    Inventors: Friedrich Richter, Jacky Vonderscher
  • Patent number: 6407091
    Abstract: The invention provides compounds of formula I and IV: wherein R1-R11 and A have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting &bgr;-lactamase enzymes, for enhancing the activity of &bgr;-lactam antibiotics, and for treating &bgr;-lactam resistant bacterial infections in a mammal. The invention also provides pharmaceutical compositions, processes for preparing compounds of formula I and IV, and novel intermediates useful for the synthesis of compounds of formula I and IV. The A can be, for example, thio, sulfinyl, or sulfonyl.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: June 18, 2002
    Assignee: Research Corporation Technologies, Inc.
    Inventors: John D. Buynak, A. Srinivasa Rao, Greg C. Adam, Sirishkumar D. Nidamarthy, Venkata Ramana Doppalapudi
  • Publication number: 20020068313
    Abstract: The present invention provides a method of identifying an agent useful in treating Crohn's disease. This method is practiced by culturing P. fluorescens under conditions that support growth; contacting the P. fluorescens with an agent; and assaying for reduced growth or viability of the P. fluorescens as compared to the growth or viability in the absence of the agent, where the reduced growth or viability of the P. fluorescens indicates that the agent is an anti-P. fluorescens agent useful in treating Crohn's disease. Also provided by the invention is a method of preventing or treating Crohn's disease in an individual by administering to the individual an effective dose of an anti-Pseudomonas vaccine.
    Type: Application
    Filed: October 12, 2001
    Publication date: June 6, 2002
    Inventors: Jonathan Braun, Bo Wei, Ashley Forbes
  • Publication number: 20020054852
    Abstract: A method of treating a specific site in a mammal with a drug comprises (a) providing a carrier material which reflects or absorbs or emits electromagnetic or mechanical vibrations enabling the monitoring of the carrier material, (b) providing a drug associated with the carrier material, (c) providing a targeting agent associated with the carrier material, the targeting agent being capable of binding to the specific site in the mammal, (d) delivering the carrier material and the drug to the specific site in the mammal, and (e) monitoring the mammal to detect arrival of the carrier material at the specific site.
    Type: Application
    Filed: December 13, 2001
    Publication date: May 9, 2002
    Inventor: Folkert Jan ten Cate
  • Patent number: 6380181
    Abstract: Catechol derivatives of general formula (I) in which R1 denotes O-acyl and R2 represents amino acid residues in the 3- and/or 4-position function as siderophores and/or as biological chelating agents for iron in gram-negative bacteria. Conjugates with antibiotics improve penetration into bacterial cells, thereby increasing antibacterial efficacy of the cells.
    Type: Grant
    Filed: September 10, 1999
    Date of Patent: April 30, 2002
    Assignee: Gruenenthal GmbH
    Inventors: Lothar Heinisch, Ute Moellmann, Matthias Schnabelrauch, Rolf Reissbrodt
  • Patent number: 6369049
    Abstract: The invention provides new fluorinated cephalosporin antibiotics of Formula I wherein Ra, Rb, Rc, Rd and Re, independently, are H, F or a C1-C6 alkyl-(Z)n— group having at least one fluorine substituent; X is O or S; Y is S, O, or —CH2—; Z is O, S, —SO—, or —SO2—; m and n independently are 0 or 1; and R1 is H, C1-C6-alkyl, phenyl or benzyl, each of which may optionally have up to three substituents selected from halo, C1-C4-alkoxy, phenyl, NO2, C1-C6-alkanoyl, benzoyl, or C1-C6-alkanoyloxy; or a physiologically acceptable salt thereof; and methods of preventing or treating or treating infection, particularly mastitis in ruminants, using these antibiotics.
    Type: Grant
    Filed: April 12, 1999
    Date of Patent: April 9, 2002
    Assignee: Eli Lilly and Company
    Inventor: Karl Robert Dahnke
  • Publication number: 20020037883
    Abstract: This invention is directed toward a method of preparing a topical composition comprising ciprofloxacin and hydrocortisone. The method involves dispersing hydrocortisone with lecithin for greater than 45 minutes prior to combining hydrocortisone with the balance of the composition.
    Type: Application
    Filed: July 16, 2001
    Publication date: March 28, 2002
    Applicant: Alcon Universal Ltd.
    Inventor: Onkar N. Singh
  • Publication number: 20020037884
    Abstract: This invention is directed toward a topical composition comprising ciprofloxacin and hydrocortisone, where the composition contains a specific grade of polyvinyl alcohol as a viscosity augmenter. The specified grade of polyvinyl alcohol is 85-90% hydrolyzed polyvinyl alcohol.
    Type: Application
    Filed: July 16, 2001
    Publication date: March 28, 2002
    Applicant: Alcon Universal Ltd.
    Inventors: Onkar N. Singh, Haresh G. Bhagat, Bhagwati P. Kabra
  • Publication number: 20020025954
    Abstract: Derivatives of 7-alkylidene cephalosporanic acid sulfone and the pharmaceutically active salts thereof are found to be potent inhibitors of &bgr;-lactamase enzymes.
    Type: Application
    Filed: July 30, 2001
    Publication date: February 28, 2002
    Applicant: Research Corporation Technologies, Inc.
    Inventors: John D. Buynak, Brian Bachmann
  • Publication number: 20020025309
    Abstract: A stable fixed dose oral pharmaceutical formulation is provided. The formulation contains at least one anti-infective agent and at least one susceptible microorganism as active ingredients. At least one of the active ingredients is coated to provide a protective barrier around the active ingredient, the active ingredients being contained in a single pharmaceutical formulation. The formulation may be a tablet, a capsule, or a powder which may be made into a stable liquid. The protective barrier protectis the susceptible micro-organism from the effect of the anti-infective agent to maintain the susceptible micro-organism in a viable form for a period of at least three months. The anti-infective agent can be an antibiotic such as an amoxycillin and the microorganism can be Lactobacillus acidophilus.
    Type: Application
    Filed: August 23, 2001
    Publication date: February 28, 2002
    Applicant: Cadila Pharmaceuticals Ltd.
    Inventors: Rajiv Indravadan Modi, Yatish Kumar Bansal, Bakulesh Mafatlal Khamar
  • Publication number: 20020013270
    Abstract: A method of treating an individual exhibiting at least one symptom of a mental disorder is provided which comprises administering to the individual an antimicrobial composition in an amount effective to inhibit or eliminate the at least one symptom of the disorder. This invention also pertains to a method of treating an individual exhibiting at least one symptom of a mental disorder by administering a probiotic mixture to replenish gastrointestinal microbes.
    Type: Application
    Filed: May 25, 2001
    Publication date: January 31, 2002
    Inventor: Ellen R. Bolte
  • Patent number: 6342493
    Abstract: Processes are provided for the preparation of orally administrable, yellow and powdery compositions essentially consisting of particles composed of a homogeneous mixture of an amorphous Cefditoren pivoxil substance with a water soluble high-molecular additive. These compositions can be produced by dissolving crystalline Cefditoren pivoxil substance and the water-soluble high-molecular additive in an aqueous solution of an acid, then neutralizing the resultant solution, to co-precipitate the product, and drying the thus precipitated product, followed by recovering the product in the form of the above-mentioned particles.
    Type: Grant
    Filed: July 7, 2000
    Date of Patent: January 29, 2002
    Assignee: Meiji Seika Kaisha Ltd.
    Inventors: Masahiro Onodera, Masamichi Sukegawa, Kiyoshi Yasui, Tatsuo Watanabe, Toyomi Sato, Yasushi Murai, Katsuharu Iinuma
  • Patent number: 6333305
    Abstract: The antibiotic TKR2999 having the physicochemical properties described below and its pharmacologically acceptable salt: (1) FAB-MS m/z 971 [M+H)]+, (2) the molecular formula: C44H78N10O14, and high-resolution FAB-MS m/z 971.5776 [M+H]+, (3) the ultraviolet absorption spectrum in methanol has an end absorption, (4) the infrared absorption spectrum by KBr method shows the major absorption wave numbers at 3320, 2920, 1680, 1540, 1210, 1140, 840, 800, and 720 cm−1, (5) aspartic acid, threonine, serine, glycine, alanine, &bgr;-alanine, and ornithine are detected by the amino acid analysis using ninhydrin reaction, and (6) the solubility is that it is soluble in methanol, and practically insoluble in hexane, chloroform, and water.
    Type: Grant
    Filed: August 2, 2000
    Date of Patent: December 25, 2001
    Assignee: Takara Shuzo Co., Ltd.
    Inventors: Kazutoh Takesako, Naoyuki Awazu, Mitsuhiro Ueno, Yoshimi Onishi, Ikunoshin Kato
  • Publication number: 20010053373
    Abstract: The present invention provides a process for preparing liquid pharmaceutical formulations on demand from tablets and capsules.
    Type: Application
    Filed: May 2, 2001
    Publication date: December 20, 2001
    Inventor: Joe D'Silva
  • Patent number: 6323193
    Abstract: This invention relates to a bioavailable oral dosage form comprising of amorphous cefuroxime axetil containing from 7 to 25% crystalline cefuroxime axetil.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: November 27, 2001
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Jitendra Krishan Somani, Indu Bhushan, Himadri Sen
  • Patent number: 6319904
    Abstract: The present invention includes a formulation which comprises an antibacterial substance and an antiulcer substance, wherein at least either of them is formulated into a gastrointestinal mucosa-adherent solid preparation. The formulation of the present invention shows long retention time in the gastrointestinal tract because of adhesion to the gastrointestinal tract mucosa, synergetically enhances the pharmaceutical effects of an antibacterial substance, specially antibiotic against Helicobacter pylori (HP) and an antiulcer substance, with very low doses of active ingredients, particularly the anti-HP antibiotic with low prevalence of side effects. The present agent is useful as an antiulcer agent, showing potent anti-HP activity.
    Type: Grant
    Filed: July 7, 1999
    Date of Patent: November 20, 2001
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Yohko Akiyama, Masafumi Nakao, Naoki Nagahara, Susumu Iwasa
  • Patent number: 6316015
    Abstract: A surface is provided with antibiotic or antiseptic properties. A solid substrate is modified by covalently fixing one or more spacers having reactive extremities via a proximate reactive extremity, and one or more antibiotic, bactericidal, viricidal or fungicidal molecules covalently bonded to a distal reactive extremity of the spacer or spacers. The spacer has formula A1—(CH2)n—A2, where: A1 is where Z=H, OH or Cl; or SiY3 where Y3 is Cl or an alkoxy group containing 1 to 3 carbon atoms; n is in the range 2 to 18; A2 is selected from the following residues: CH═CH2, OH, halogen or where Z=H, OH or Cl.
    Type: Grant
    Filed: February 1, 1999
    Date of Patent: November 13, 2001
    Assignees: Institut Curie, Centre National de la Recherche Scientifique
    Inventors: Francis Rondelez, Pascal Bezou, Othman Bouloussa
  • Publication number: 20010034339
    Abstract: Suspension formulations containing dexamethasone and ciprofloxacin are disclosed. The formulations contain a nonionic polymer, a nonionic surfactant and an ionic tonicity agent, but are physically stable and easily re-suspended. The formulations are intended for topical application to the eye, ear or nose.
    Type: Application
    Filed: May 25, 2001
    Publication date: October 25, 2001
    Inventors: Onkar N. Singh, Haresh G. Bhagat
  • Patent number: 6303572
    Abstract: According to the present invention there is provided a method for the treatment or prophylaxis of acidic gut syndrome resulting from the accumulation of acid and production of endotoxin in the gastrointestinal tract of a human or an animal, said accumulation resulting from the fermentation of carbohydrate in the gastrointestinal tract of said human or animal, wherein said method comprises administering to said human or animal an effective amount of an active agent capable of preventing or controlling acid and endotoxin accumulation in the gastrointestinal tract.
    Type: Grant
    Filed: February 10, 2000
    Date of Patent: October 16, 2001
    Assignee: University of New England, of Armidale
    Inventor: James Baber Rowe